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Background: JMML is a rare, highly aggressive clonal
myeloproliferative disorder typically diagnosed in infants
and young children. Allogeneic HSCT is widely accepted as
the standard curative therapy for JMML, but success is
limited by engraftment failure or disease relapse. Five-year
overall survival ranges from 50-55%.
Objective: Evaluate our single center allogeneic HSCT out-
comes for JMML.
Methods: We retrospectively reviewed data on all JMML
patients who received allogeneic HSCT at our center from
1998-2013. Data collected were age at diagnosis and HSCT,
time to HSCT, sex, race/ethnicity, conditioning regimen, stem
cell source, total nucleated cell dose, graft-versus-host dis-
ease (GVHD) prophylaxis, time to neutrophil (absolute
neutrophil count, ANC) and platelet (PLT) engraftment,
presence of acute and/or chronic GVHD, relapse, cause of
death, and last time of follow-up. Descriptive statistics were
used for data analysis.
Results: Eleven patients were diagnosed with JMML and
received allogeneic HSCT over the last 15 years in our center.
Median age at diagnosis was 18.6 (range 2.9-42.1) months.
Six of 11 (54.5%) were males. Eight of 11 (72.7%) were His-
panic, 2/11 White (18.2%), and 1/11 Black (9.1%). Median age
at HSCT was 26.2 months (range 4.1-51.0) with median time
to HSCT 6.1 months (range 1.2-17.1). All received myeloa-
blative conditioning; 8/11 (72.7%) received busulfan, cyclo-
phosphamide, and melphalan with 5/11 (45.5%) receiving
ATG. GVHD prophylaxis was CsA+steroids (4), CsA+MMF (1),
and CsA+MTX (1) and tacrolimus+MTX (5). Stem cell source
was unrelated umbilical cord blood (UCB) (7) and bone
marrow (BM) (4). UCB HLA-disparities were 5/6 (5), 4/6 (1),
and 3/6 (1). Three of 4 received matched related donor
(MRD) BMwhile 1 received matched unrelated donor (MUD)
BMT. Median time to ANC > 500/mL was 21 days, to PLT
>20,000/mL was 33 days, and to PLT >50,000/mL was 44.5
days. One patient (UCB) had engraftment failure and
received a 2nd HSCT with UCB after 200 cGy total body
irradiation+ﬂudarabine+ATG. Acute GVHD occurred in 6/11
(54.5%), limited chronic GVHD in 2/11 (18.2%) and extensive
chronic GVHD in 1/11 (9.1%). With a median follow-up of 4.2
(range_0.1-15.2) years, 8/11 patients are alive (72.7%). Cause
of death was progression to AML (1), sinusoidal obstructive
liver syndrome and HHV6 encephalitis (1) and chronic GVHD
with bronchiolitis obliterans (1).
Conclusions: The overall survival for JMML in our center
(72.7%) over the last 15 years is comparable to published
data. Despite historically poor disease-free survival, nopatients have experienced recurrent JMML post-HSCT in our
cohort. We hypothesize that this observed trend toward
superior survival may be due to undeﬁned favorable char-
acteristics in our predominantly Hispanic patient population
and younger age at diagnosis. Our experience supports the
use of HLA-mismatched UCB for unrelated donor HSCT in
JMML.
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Introduction: Failure to harvest sufﬁcient stem cells from
either Bone marrow (BM) or peripheral blood is a rare but
known impasse in stem cell transplantation (SCT). If second
boost is not given within 96 hours then chances of rejection
post second SCT are very high. Plerixafor (Mozobil) is an
effective drug for rapid (within 24 hr) stem cell mobilizer as
it reduces CD34+ hematopoietic stem cells anchoring to the
BM microenvironment through reversible inhibition of the
SDF-1a/CXCR4 axis.
Case: A 4-year-old girl of thalassemia major underwent allo-
SCT from a 6/6 loci HLA-identical 17 year old sister. Pre-
transplant work-up showed no discernible pathology except
bidirectional major ABO mismatch. Conditioning regimen
consisted of intravenous busulphan (12.8 mg/kg),cyclo-
phosphamide (200mg/kg) and ATG (90mg/kg). Pre depletion
and after red cell and plasma depletion, harvested CD34+ cell
dose was 2 and 0.5 million/kg/recipient respectively. In view
of the failed BM harvest, a decision was eventually made,
after obtaining the consent of the parents, to attempt donor
CD34+ cell mobilization with plerixafor and G-CSF. The
donor received G-CSF (5 mcg/kg s.c.) for 3 consecutive days
at 1800 hr, while plerixafor (240 mcg/kg s.c.) was given 15 hr
later, after last dose of G-CSF. Five hour after plerixafor
dosing, the donor’s WBC had reached 64.0 x 109/L. The har-
vested CD34+ cell dose of 17.6 x 106/kg/recipient infused.
Donor tolerated plerixafor well without any adverse effects.
Her neutrophil and platelets engrafted on day +19 and +21
respectively. The patient and donor remain well 2 months
after SCT. Donor would be followed every 6 monthly for next
3 years for any long term adverse effects of plerixafor.
Conclusion: Our case highlights that plerixafor is an effec-
tive agent for rapid PBSC mobilization from a normal healthy
donor, if initial BM harvest fails. However, donor should be
monitored for the long term safety of plerixafor.
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Background: Although management of CML has changed
dramatically in the era of tyrosine kinase inhibitors (TKIs),
Abstracts / Biol Blood Marrow Transplant 20 (2014) S165eS183 S181there is still a dichotomy in outcome for patients who pre-
sent in Chronic Phase (CP) versus Accelerated Phase (AP) or
with acute leukemic blast crisis (BC) CML. For patients with
CP-CML prognosis is excellent when treated with TKIs alone
while for patients with AP- or BC-CML, the goal of therapy is
to get back into chronic phase CML and then proceed to an
allogeneic bone marrow transplant (allo-BMT). Even with
this intensiﬁed approach, patients with advanced CML his-
torically have had a poor prognosis with an OS ofw65% one
year after allo-BMT. In the pre-TKI era roughly 20% of patients
with CML would progress to blast crisis. This has declined to
w1% in the TKI era, but the overall survival of these patients
has not changed.
Methods: After obtaining IRB approval, we reviewed the
medical records of all patients evaluated for allo-BMT for
CML at our institution between January 1, 2010 and June 30,
2013. There were ﬁve children who presented with CML in
accelerated phase or blast crisis.
Results: Five patients developed advanced stage CML during
the observed period. Ages ranged from 12-18 years old at the
time of transplant (median age 13). The male:female ratio
was 4:1. 4/5 presented in lymphoid blast crisis and 1/5 in
accelerated phase. All patients were started on imatinib
though two required a second or third line TKI to achieve
stable phase prior to transplant. Prior to transplant, all
patients were in at least a morphologic and cytogenetic
remission; 3/5 also were in a molecular remission. 4/5 pa-
tients received a matched unrelated donor transplant; the
other underwent a matched sibling transplant. Conditioning
was TBI (1440 cGy) and Cyclophosphamide. GVHD prophy-
laxis was Cyclosporine and Methotrexate with Prednisone
added for unrelated donors per our institutional standard.
Median day of engraftment was + 24. 1/5 patients developed
stage 2-4 aGVHD and none developed grade 3-4 aGVHD.
TKI’s were restarted in all patients (median day 114) with a
goal of continuing until 2 years post transplant. One patient
developed joint pain and night sweats which resolved with
dose reduction, another myelosuppression which resolved
with TKI holiday and dose reduction. All patients are alive
and remain in molecular remission with undetectable BCR-
ABL transcript with an average duration of remission of 435
days [190-1347].
Discussion: The outcomes of children with CML presenting
in blast crisis in the era of TKIs has not been previously
documented. The use of TKI’s pre- and post-transplant may
lead to improved disease free survival for this group. Disease
control prior to SCT and close monitoring remain essential
for optimal outcome.268
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Background: Congenital hydrocephalus affects 0.3 to 1.5 per
1000 live births, is typically diagnosed in utero, and may
occur in isolation or as a result of a genetic or other
underlying cause. Current standard therapy involves ven-
triculoperitoneal shunt placement shortly after birth to
divert the ﬂow of cerebrospinal ﬂuid and decreaseintracranial pressure. However, survivors face the sequelae of
brain injury resulting from the prolonged hydrocephalic
state in utero. Umbilical cord blood (CB) has been shown to
lessen the clinical and radiographic impact of hypoxic brain
injury and stroke in animal models. Based on this data, we
began to treat infants with congenital hydrocephalus with
multiple autologous CB infusions during the ﬁrst 1-2 years of
life to determine the safety and feasibility of the procedure.
Methods: Parents of children diagnosed with congenital
hydrocephalus in utero elected to store their child’s CB in a
private or public bank as a directed donor. CB units were
deemed eligible based on results of, cell count, sterility,
potency and infectious disease screening. On the day of
infusion, CB units were thawed and washed in dextran-al-
bumin and infused via peripheral IV in the outpatient clinic
after premedicationwith acetaminophen, diphenhydramine,
and methylprednisolone. When possible, CB units were
fractionated to allow for multiple doses over time.
Results: Since 2006, 70 patients with congenital hydro-
cephalus have been treated with 129 autologous CB in-
fusions. Most babies received repeated doses, for a total of 2
(N¼24), 3 (N¼12), or 4 (N¼4) infusions. Median age at the
ﬁrst infusion was 2 months (range 6 days e 4 years). Median
cell doses per infusion were TNC 2.0x107/kg (range 0.1-
13.3x107/kg) and CD34 count 0.7 x105/kg (range 0.04-
6.4x105/kg). The infusions were well tolerated, with no acute
or chronic adverse events. Anecdotally, parents report that
their children are making developmental gains after autol-
ogous CB infusion.
Conclusions: Autologous CB infusion is safe and feasible in
babies with congenital hydrocephalus. Since the diagnosis is
typically made in utero, there is sufﬁcient time to plan for CB
collection prior to delivery. As the patients are so young and
small at the time of treatment, a single CB unit can often be
fractionated to permit a multiple dosing strategy. While in-
fants make developmental progress after the infusions,
additional studies are necessary to determine if these gains
are related to the CB treatment.269
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In Asia, where the chance of ﬁnding a HLA 10/10 allele
matched adult donor in a short time is low; stem cell donors
including mismatched unrelated cord blood and family
haploidentical stem cell donors are feasible alternatives.
Between Jan 2007 and Sep 2013, a total of 14 haploidentical
stem cell transplants (SCT) in 13 patients were performed in
our Pediatric SCT Program. Of the 9 boys and 4 girls, SCT was
performed in 2 for non-malignant diseases (1 Hurler’s, 1
Hepatitis Associated Severe Aplastic Anemia) and 11 for very
high risks malignancies (4 ALL, 3 AML, 3 Lymphoma, 1 MDS/
RAEB). Preparative regimen was tailored to pre-morbid sta-
tus and was reduced intensity (N¼6) which included single
TBI 2 Gy  Fludarabine/ Cyclophosphamide or full prepara-
tion (N¼8) with Fludarabine, Thiotepa, Melphalan, ATG
(Thymoglobulin), Rituximab and TLI 6-8Gy or TBI 6Gy.
